These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 9151342)
21. Current dilemmas in the management of inflammatory bowel disease. Rutgeerts P Eur J Surg Suppl; 2002; (587):58-61. PubMed ID: 16144202 [TBL] [Abstract][Full Text] [Related]
22. [Biological therapies for treatment of chronic inflammatory bowel diseases. Status update]. Metzler J; Stange EF Med Klin (Munich); 2002 May; 97(5):290-7. PubMed ID: 12078390 [TBL] [Abstract][Full Text] [Related]
23. Circulating antibodies to bovine albumin in ulcerative colitis and Crohn's disease. Characterization of the antibody response. Falchuk KR; Isselbacher KJ Gastroenterology; 1976 Jan; 70(1):5-8. PubMed ID: 1245283 [TBL] [Abstract][Full Text] [Related]
25. [Anti-TNF antibodies in the treatment of intestinal inflammatory disease]. Hinojosa J Gastroenterol Hepatol; 2000 May; 23(5):250-7. PubMed ID: 10902280 [No Abstract] [Full Text] [Related]
26. Anti-Saccharomyces cerevisiae mannan antibodies in inflammatory bowel disease: comparison of different assays and correlation with clinical features. Annese V; Piepoli A; Perri F; Lombardi G; Latiano A; Napolitano G; Corritore G; Vandewalle P; Poulain D; Colombel JF; Andriulli A Aliment Pharmacol Ther; 2004 Nov; 20(10):1143-52. PubMed ID: 15569117 [TBL] [Abstract][Full Text] [Related]
27. [Infliximab therapy for Crohn's disease - a practical guideline: actualised consensus of the working group for chronic inflammatory bowel diseases of the Austrian Society for Gastroenterology and Hepatology]. Reinisch W; Dejaco C; Feichtenschlager T; Haas T; Kaser A; Miehsler W; Novacek G; Petritsch W; Platzer R; Tilg H; Vogelsang H; Knoflach P; Z Gastroenterol; 2011 Apr; 49(4):534-42. PubMed ID: 21442574 [TBL] [Abstract][Full Text] [Related]
29. Alterations in serum anti-alpha-galactosyl antibodies in patients with Crohn's disease and ulcerative colitis. D'Alessandro M; Mariani P; Lomanto D; Bachetoni A; Speranza V Clin Immunol; 2002 Apr; 103(1):63-8. PubMed ID: 11987986 [TBL] [Abstract][Full Text] [Related]
30. New and emerging biologics in the treatment of inflammatory bowel disease: quo vadis? Danese S; Angelucci E Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S217-27. PubMed ID: 20117345 [TBL] [Abstract][Full Text] [Related]
35. [Follow-up study of the development of autoantibodies in patients with chronic inflammatory bowel disease under anti-CD4 therapy]. Buchwald S; Emmrich J; Seyfarth M; Emmrich F Immun Infekt; 1993 Apr; 21 Suppl 1():34-5. PubMed ID: 8344685 [TBL] [Abstract][Full Text] [Related]
36. Review article: a critical approach to new forms of treatment of Crohn's disease and ulcerative colitis. Seegers D; Bouma G; Peña AS Aliment Pharmacol Ther; 2002 Jul; 16 Suppl 4():53-8. PubMed ID: 12047261 [TBL] [Abstract][Full Text] [Related]
37. Biological therapies for inflammatory bowel diseases. Rutgeerts P; Vermeire S; Van Assche G Gastroenterology; 2009 Apr; 136(4):1182-97. PubMed ID: 19249397 [TBL] [Abstract][Full Text] [Related]
39. Digestive Disease Week 2006. Therapies for Crohn's disease and ulcerative colitis. 21-15 May 2006, Los Angeles, CA, USA. Aylett P IDrugs; 2006 Jul; 9(7):452-4. PubMed ID: 16821150 [No Abstract] [Full Text] [Related]
40. Interleukin-12 antagonists as new therapeutic agents in inflammatory bowel disease. Schmidt C; Marth T; Wittig BM; Hombach A; Abken H; Stallmach A Pathobiology; 2002-2003; 70(3):177-83. PubMed ID: 12571423 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]